Key Highlights
- Fiscal 2027 second quarter Revenue rose 9% to USD 1.6 billion, with constant currency organic growth of 8%, and as reported Net Income was USD 213.7 million, or USD 2.19 per diluted share.
- Adjusted EPS rose to USD 2.94 from USD 2.47, and the pre-tax benefit of Tariff refunds on as reported results was approximately USD 20 million in the quarter.
- STERIS (NYSE:STE) raised its fiscal 2027 adjusted EPS outlook to USD 11.35 to USD 11.55 from USD 11.10 to USD 11.30, including about USD 0.18 from tariff refunds received year-to-date.
- Life Sciences revenue rose 18% to USD 170.6 million, and the segment's organic growth outlook for the year was lifted to 9% to 10% from 6% to 7%.
Tariff Refunds Add to a Solid Quarter
STERIS (NYSE:STE) announced results for the quarter ended September 30, 2026 on November 4, 2026. As reported net income was USD 213.7 million versus USD 191.9 million, and adjusted net income was USD 286.8 million versus USD 244.5 million. Adjusted EPS excludes amortization of acquired intangibles, deal and integration costs, restructuring and other unusual items. Refunds of tariffs gave a pre-tax benefit of about USD 20 million, while gross tariff costs stayed flat at USD 15 million. So the USD 0.47 adjusted EPS rise (calculated) is not all underlying. The company called the performance solid and expects another record year, helped by Demand and commercial execution, though the release gives no split of the refund effect on quarterly EPS.
Life Sciences Leads While AST Capital Equipment Falls
Healthcare revenue grew 9% to USD 1.1 billion, with service up 10%, consumables up 10% and capital equipment up 4%, while Operating Income was USD 269.2 million versus USD 259.5 million. Applied Sterilization Technologies revenue rose 5% to USD 295.6 million, with a 21% decline in capital equipment and operating income of USD 132.1 million. Life Sciences operating income rose to USD 75.8 million from USD 59.9 million on price, productivity, Volume and mix, as capital equipment revenue jumped 53%, consumables rose 9% and service rose 5%. Management raised the segment's full-year organic growth outlook on that strength. Management lowered the AST organic growth outlook to 6% to 7% from 7% to 8%.
Outlook, Restructuring and Cash Flow Softness
Fiscal 2027 revenue growth expectations are unchanged at 7% to 8% as reported and 6% to 7% in constant currency organic terms. A second restructuring plan, mainly in Healthcare, carries about USD 45 million of charges, including USD 25 million in the quarter, and is expected to deliver annualized savings of about USD 9 million. Free cash flow for six months was USD 492.5 million versus USD 527.7 million because Working Capital contributed less, partly offset by higher net income. Net cash from operations over the six months was USD 656.1 million versus USD 707.8 million. A proposed Acquisition of Xodus Medical is not yet in the outlook, which will be revised after closing.
Where Things Stand
About USD 0.18 of the outlook increase comes from tariff refunds, so the raise is partly one-off. STERIS (NYSE:STE) still grew revenue 9% with strength in Life Sciences and Healthcare services, and the new guidance of USD 11.35 to USD 11.55 reflects stable underlying performance. Next markers are the November 5, 2026 conference call, the closing of the Xodus Medical deal, restructuring savings and whether AST capital equipment recovers. The release gave no stock price reaction.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...